Water Island Capital LLC bought a new stake in shares of Immune Design Corp (NASDAQ:IMDZ) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 608,000 shares of the biotechnology company’s stock, valued at approximately $3,557,000.

Several other large investors have also modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in Immune Design by 48.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 661,961 shares of the biotechnology company’s stock valued at $2,284,000 after buying an additional 214,935 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Immune Design in the 3rd quarter valued at about $508,000. Marshall Wace LLP acquired a new position in Immune Design in the 3rd quarter valued at about $36,000. Vanguard Group Inc grew its position in shares of Immune Design by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 1,615,442 shares of the biotechnology company’s stock worth $5,574,000 after purchasing an additional 11,006 shares in the last quarter. Finally, Personal Capital Advisors Corp grew its position in shares of Immune Design by 56.3% during the 4th quarter. Personal Capital Advisors Corp now owns 37,500 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 13,500 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors.

IMDZ has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Immune Design from a “hold” rating to a “sell” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada lowered shares of Immune Design from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $9.00 to $6.00 in a research report on Friday, February 22nd. Finally, HC Wainwright lowered shares of Immune Design from a “buy” rating to a “neutral” rating in a research report on Thursday, February 21st. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The company currently has an average rating of “Hold” and an average price target of $5.17.

NASDAQ:IMDZ remained flat at $$5.85 on Wednesday. The company has a market capitalization of $282.96 million, a P/E ratio of -3.34 and a beta of 3.48. Immune Design Corp has a 12 month low of $1.10 and a 12 month high of $5.85.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2019/05/15/water-island-capital-llc-takes-3-56-million-position-in-immune-design-corp-imdz.html.

Immune Design Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

See Also: Understanding Analyst Recommendations

Want to see what other hedge funds are holding IMDZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immune Design Corp (NASDAQ:IMDZ).

Institutional Ownership by Quarter for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.